IHC MARKERS (CD10,ER,PR)

The IHC Markers (CD10, ER, PR) test is a specialized immunohistochemistry (IHC) diagnostic panel used to detect the expression of CD10, Estrogen Receptor (ER), and Progesterone Receptor (PR) in tissue samples. This panel is widely used in pathology for tumor classification, hormone receptor evaluation, and differentiation of specific benign and malignant tissue lesions.

Each marker in this panel provides important diagnostic information:

• CD10: A cell surface enzyme marker commonly used to identify stromal cells, certain hematologic malignancies, and specific epithelial tumors.
• ER (Estrogen Receptor): Detects estrogen receptor expression, especially important in breast and gynecologic cancers.
• PR (Progesterone Receptor): Detects progesterone receptor expression and helps evaluate hormone sensitivity of tumors.

Together, these markers provide a comprehensive assessment of tissue characteristics and are especially useful in diagnosing breast tumors, gynecologic lesions, endometrial stromal tumors, and hormone-sensitive cancers.

Benefits of the Test

The IHC CD10, ER, PR panel offers several important clinical benefits:

• Detects hormone receptor status accurately
• Helps classify hormone-sensitive tumors
• Assists in diagnosing breast and gynecologic cancers
• Differentiates benign and malignant tissue lesions
• Supports prognosis assessment
• Guides hormone therapy decisions

This test is critical for personalized oncology care.

Why Doctors Recommend This Test

Doctors recommend the CD10, ER, PR panel when hormone receptor analysis and tissue classification are needed.

It is commonly advised for:

• Breast cancer diagnosis and receptor profiling
• Endometrial stromal lesion evaluation
• Gynecologic tumor classification
• Confirmation of hormone-sensitive cancers
• Personalized treatment planning

The results help oncologists determine prognosis and select targeted hormone-based therapies.

Preparation Before Test

No special preparation is required from the patient. The test is performed on previously collected tissue biopsy or surgical specimens.

Normal Reporting Time

The typical turnaround time for the CD10, ER, PR panel is 3 to 5 working days, depending on tissue complexity and laboratory workflow.

Who Should Take This Test

This test is recommended for:

• Patients diagnosed with breast cancer
• Individuals with suspected gynecologic tumors
• Patients requiring hormone receptor testing
• Cases needing tissue classification confirmation
• Oncology patients requiring personalized therapy planning

The IHC CD10, ER, PR panel is an important diagnostic tool in pathology. It provides accurate receptor analysis and tissue classification, helping doctors make evidence-based treatment decisions and improve patient outcomes.